Support teaching, research, and patient care.
Dr. Dita Gratzinger is a hematopathologist who is dedicated to excellent patient care, to educating the hematopathologists of tomorrow, and to improving both by harnessing strengths across institutional and disciplinary lines. Dr. Gratzinger studies the architecture of supporting cells in the microenvironment as well as diagnosis of lymphoma on small volume specimens, and has a special interest in the role of patient-specific factors in manifestation of hematolymphoid disease, including immunodeficiency and dysregulation-related lymphoid proliferations. She is the founding chair of a multi-institutional consortium, the Cyto-Heme Interinstitutional Collaborative, which brings together hematopathologists, cytopathologists, and oncologists to optimize the benefits of small volume biopsy to lymphoma patients. She also heads the Stanford hematopathology service. Dr. Gratzinger received her B.A. from the University of California at Berkeley, her M.D. and PhD from Yale University, and completed her anatomic pathology residency, surgical pathology fellowship, and hematopathology fellowship at Stanford University.
I have research interests in the interaction of hematolymphoid neoplasia with the microenvironment. For example, I use a combination of immunohistochemistry, immunofluorescence and image analysis techniques to evaluate the mesenchymal stromal cell compartment in myelodysplastic syndrome (pre-leukemic bone marrow failure disorder). I also have interests in lymphoma vasculature and the tropism of lymphoma for specific types of vasculature.
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
A research study on the diagnosis of spread of disease for children who have been diagnosed
with solid tumors using a new whole body imaging technique and a new MR contrast agent
(ferumoxytol). Standard tests that are used to determine the extent and possible spread of a
child's disease include magnetic resonance (MR) imaging, computed tomography (CT), Positron
Emission Tomography (PET) as well as bone scanning, and metaiodobenzylguanidine (MIBG)
scanning. The purpose of this study is to determine if newer imaging tests referred to as
whole body diffusion-weighted MR and whole body PET/MR can detect the extent and spread of
the disease as accurately or even better as the standard tests (CT, MR and/or PET/CT). The
advantage of the new imaging test is that it is associated with no or significantly reduced
radiation exposure compared to standard CT and PET/CT imaging tests. The results of whole
body MR and PET/MR will be compared with that of the conventional, standard imaging studies
for tumor detecting.
View full details